title: Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors.
abstract: Primary mediastinal large B-cell lymphoma (PMLBCL) is a unique clinico-pathological subtype, for which there is no optimal therapy yet. We evaluated clinical characteristics and prognostic factors in 39 consecutive, previously untreated Chinese patients with PMLBCL. The median age was 28 years (range 16-72 years). The majority of patients were stage I/II (23 cases, 59%). Bulky mediastinal mass was present in 18 cases (46%). The 3-year overall survival (OS) and progression-free survival (PFS) rates were 70 and 64%, respectively. Cox regression analysis showed that low serum albumin was an independent prognostic predictor of both OS (P = 0.002) and PFS (P = 0.001). Other prognostic factors for OS were extra-thoracic involvement (P = 0.016) and B symptoms (with borderline significance, P = 0.053). The addition of radiotherapy to chemotherapy seemed to have a favourable impact on OS (P = 0.034) and PFS (P = 0.039). The addition of rituximab to chemotherapy improved the survival trend, but added no significant benefit (OS: 57 vs. 84%, P = 0.287; PFS: 53 vs. 73%, P = 0.371). Our data additionally suggest that low serum albumin is a novel prognostic predictor for PMLBCL, and could be useful in determining treatment options in the clinic.
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, 651 Dong Feng Rd East, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Ying-Jie
authors.initials: YJ
authors.lastname: Zhu
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, 651 Dong Feng Rd East, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Jia-Jia
authors.initials: JJ
authors.lastname: Huang
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, 651 Dong Feng Rd East, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Xia
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, 651 Dong Feng Rd East, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhao
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, 651 Dong Feng Rd East, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Wen-Qi
authors.initials: WQ
authors.lastname: Jiang
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, 651 Dong Feng Rd East, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Tong-Yu
authors.initials: TY
authors.lastname: Lin
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, 651 Dong Feng Rd East, Guangzhou, Guangdong, People's Republic of China.
authors.forename: Hui-Qiang
authors.initials: HQ
authors.lastname: Huang
authors.affiliation: State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Sun Yat-sen University, 651 Dong Feng Rd East, Guangzhou, Guangdong, People's Republic of China. lzmlzmlzm@yahoo.com.
authors.forename: Zhi-Ming
authors.initials: ZM
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D044466:Asian People; D003131:Combined Modality Therapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008479:Mediastinal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D000069283:Rituximab; D012709:Serum Albumin / Q000032:analysis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D012709:Serum Albumin; D000069283:Rituximab